Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America

Table 5 Multivariate analysis of developing active tuberculosis by Poisson regression in patients with inflammatory bowel disease under treatment from a referral center

Model	Anti-TNFα	P value	Azathioprine	P value	Anti-TNFα + azathioprine	P value
	RR (95%CI)		RR (95%CI)		RR (95%CI)
No adjustment	3.93 (1.01-15.32)	0.048	5.85 (1.20-28.56)	0.029	9.03 (2.37-34.35)	0.001
Sex	3.13 (0.69-14.27)	0.14	5.63 (1.15-27.86)	0.033	7.85 (1.88-32.77)	0.005
Sex, type IBD	6.43 (2.33-17.74)	< 0.001	6.91 (1.50-31.80)	0.013	13.53 (4.50-40.78)	< 0.001
Sex, type IBD, latent TB	10.84 (4.26-27.60)	< 0.001	5.57 (0.86-36.06)	0.071	15.81 (6.07-41.23)	< 0.001
Sex, age, type IBD, latent TB	10.34 (4.28-24.96)	< 0.001	6.27 (1.03-38.05)	0.046	17.81 (5.91-53.67)	< 0.001

Anti-TNFα: Anti-tumor necrosis factor alpha; IBD: Inflammatory bowel disease; RR: Relative risk; TB: Tuberculosis.